Stiefel Laboratories, Inc. today announced that the U.S. Food and Drug Administration has approved its new drug application for Extina® Foam, 2% for the treatment of seborrheic dermatitis.
From: biz.yahoo.com
R) for the Treatment of Seborrheic Dermatitis
Posted by Ruslan Abuzant at 7:02 AM
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment